• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Rubosixtaurin and other PKC inhibitors in diabetic retinopathy and macular edema. Review.

作者信息

Gálvez M Isabel López

机构信息

IOBA, Campus Miguel Delibes, Universidad de Valladolid, Valladolid, Spain.

出版信息

Curr Diabetes Rev. 2009 Feb;5(1):14-7. doi: 10.2174/157339909787314167.

DOI:10.2174/157339909787314167
PMID:19199893
Abstract

Diabetic retinopathy (DR) and diabetic macular edema (DME) are frequent long term ocular complications in diabetic patients and may produce serious effects on visual acuity (VA), sometimes leading to blindness. The high and increasing prevalence of diabetes worldwide suggests that both complications will continue to be the main cause of vision loss and associated impairment for a long time [1]. The development and progression of DR is related to blood glucose concentration and is slowed by intensive glycemic control [2].

摘要

相似文献

1
Rubosixtaurin and other PKC inhibitors in diabetic retinopathy and macular edema. Review.
Curr Diabetes Rev. 2009 Feb;5(1):14-7. doi: 10.2174/157339909787314167.
2
Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.鲁比前列酮对糖尿病视网膜病变患者视力丧失的影响。
Ophthalmology. 2006 Dec;113(12):2221-30. doi: 10.1016/j.ophtha.2006.07.032. Epub 2006 Sep 20.
3
Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.鲁比前列酮对与长期糖尿病性黄斑水肿相关的视力下降的影响。
Invest Ophthalmol Vis Sci. 2009 Jan;50(1):1-4. doi: 10.1167/iovs.08-2473. Epub 2008 Aug 15.
4
Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.鲁比前列酮对与长期糖尿病性黄斑水肿相关的视力下降的影响。
Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6890; author reply 6890-1. doi: 10.1167/iovs.09-4106.
5
The potential role of PKC beta in diabetic retinopathy and macular edema.蛋白激酶Cβ在糖尿病性视网膜病变和黄斑水肿中的潜在作用。
Surv Ophthalmol. 2002 Dec;47 Suppl 2:S263-9. doi: 10.1016/s0039-6257(02)00391-0.
6
The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies.口服蛋白激酶 Cβ抑制剂罗格列酮在两项 3 期研究中对视力丧失的影响。
Invest Ophthalmol Vis Sci. 2013 Mar 11;54(3):1750-7. doi: 10.1167/iovs.12-11055.
7
Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2.口服蛋白激酶 Cβ 抑制剂罗格列酮治疗糖尿病视网膜病变:蛋白激酶 Cβ 抑制剂-糖尿病视网膜病变研究和蛋白激酶 Cβ 抑制剂-糖尿病视网膜病变研究 2 中 813 例(1392 只眼)糖尿病视网膜病变患者的疗效、安全性和视力丧失的原因。
Retina. 2011 Nov;31(10):2084-94. doi: 10.1097/IAE.0b013e3182111669.
8
Treatment of diabetic retinopathy with protein kinase C subtype Beta inhibitor.用蛋白激酶Cβ亚型抑制剂治疗糖尿病性视网膜病变。
Dev Ophthalmol. 2007;39:157-165. doi: 10.1159/000098506.
9
Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors.糖尿病视网膜病变的潜在新型药物疗法:蛋白激酶C抑制剂
Am J Ophthalmol. 2002 May;133(5):693-8. doi: 10.1016/s0002-9394(02)01321-1.
10
The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial.鲁比前列酮对中重度至极重度非增殖性糖尿病视网膜病变患者视力丧失的影响:蛋白激酶Cβ抑制剂糖尿病视网膜病变研究(PKC-DRS)多中心随机临床试验的初步结果。
Diabetes. 2005 Jul;54(7):2188-97. doi: 10.2337/diabetes.54.7.2188.

引用本文的文献

1
Oxidative Stress: Signaling Pathways, Biological Functions, and Disease.氧化应激:信号通路、生物学功能与疾病
MedComm (2020). 2025 Jul 1;6(7):e70268. doi: 10.1002/mco2.70268. eCollection 2025 Jul.
2
Cellular targets in diabetic retinopathy therapy.糖尿病视网膜病变治疗中的细胞靶点。
World J Diabetes. 2021 Sep 15;12(9):1442-1462. doi: 10.4239/wjd.v12.i9.1442.
3
Protein Kinase C-Independent Inhibition of Organic Cation Transporter 1 Activity by the Bisindolylmaleimide Ro 31-8220.双吲哚马来酰亚胺Ro 31-8220对有机阳离子转运体1活性的蛋白激酶C非依赖性抑制作用
PLoS One. 2015 Dec 10;10(12):e0144667. doi: 10.1371/journal.pone.0144667. eCollection 2015.
4
Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets.糖尿病视网膜病变的分子机制、一般预防策略及新的治疗靶点。
Biomed Res Int. 2014;2014:801269. doi: 10.1155/2014/801269. Epub 2014 Jul 6.
5
Atypical protein kinase C in cell motility.非典型蛋白激酶 C 与细胞运动。
Cell Mol Life Sci. 2013 Sep;70(17):3057-66. doi: 10.1007/s00018-012-1192-1. Epub 2012 Oct 25.
6
Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy.治疗增生性糖尿病视网膜病变中炎症和血管生成介质的干预措施。
Mediators Inflamm. 2012;2012:629452. doi: 10.1155/2012/629452. Epub 2012 Sep 17.